Celgene Corporation (CELG) Holder Tekla Capital Management LLC Lifted Stake by $8.62 Million as Stock Value Rose

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment increased to 0.76 in Q1 2019. Its up 0.12, from 0.64 in 2018Q4. It increased, as 108 investors sold CELG shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported. Hussman Strategic Inc holds 0.81% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 35,000 shares. Wedgewood Investors Inc Pa accumulated 2,500 shares or 0.37% of the stock. Corvex Limited Partnership invested in 27,404 shares or 0.18% of the stock. Altfest L J Communication accumulated 0.09% or 22,570 shares. Strs Ohio holds 0.28% in Celgene Corporation (NASDAQ:CELG) or 658,360 shares. Parallax Volatility Advisers LP reported 26,426 shares or 0% of all its holdings. Silvercrest Asset Mgmt Group Ltd Liability Co holds 0.04% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 42,990 shares. Triangle Securities Wealth Mngmt invested 0.11% of its portfolio in Celgene Corporation (NASDAQ:CELG). Global Endowment Management Limited Partnership holds 0.07% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 5,590 shares. Atria Invs Limited Liability Corporation has 0.07% invested in Celgene Corporation (NASDAQ:CELG). Boussard Gavaudan Ltd Liability Partnership stated it has 1.95 million shares. Advisory Alpha Ltd Company invested in 638 shares. Moreover, Ancora Limited Co has 0.08% invested in Celgene Corporation (NASDAQ:CELG) for 19,466 shares. Pictet Bankshares And Limited has 36,160 shares for 1.5% of their portfolio. B Riley Wealth Mgmt has 2,266 shares.

Since February 7, 2019, it had 0 insider buys, and 1 insider sale for $2.05 million activity.

Tekla Capital Management Llc increased its stake in Celgene Corporation (CELG) by 6.64% based on its latest 2019Q1 regulatory filing with the SEC. Tekla Capital Management Llc bought 91,704 shares as the company’s stock rose 5.82% with the market. The institutional investor held 1.47M shares of the major pharmaceuticals company at the end of 2019Q1, valued at $139.03 million, up from 1.38 million at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Celgene Corporation for a number of months, seems to be bullish on the $64.84B market cap company. The stock decreased 0.52% or $0.48 during the last trading session, reaching $91.93. About 3.03M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 11.31% since July 14, 2018 and is uptrending. It has outperformed by 6.88% the S&P500.

Tekla Capital Management Llc, which manages about $1.06B and $2.46 billion US Long portfolio, decreased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 320,879 shares to 890,989 shares, valued at $13.97 million in 2019Q1, according to the filing. It also reduced its holding in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 120,583 shares in the quarter, leaving it with 375,705 shares, and cut its stake in Unitedhealth Group Incorporated (NYSE:UNH).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “Is bluebird bio a Buy? – The Motley Fool” on July 07, 2019, also Nasdaq.com with their article: “5 Best-Performing S&P 500 Stocks So Far This Year – Nasdaq” published on June 21, 2019, Nasdaq.com published: “Validea’s Top Five Healthcare Stocks Based On Warren Buffett – 6/16/2019 – Nasdaq” on June 16, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “AbbVie to Buy Allergan: Prescribed ETFs – Nasdaq” published on June 26, 2019 as well as Nasdaq.com‘s news article titled: “Notable Monday Option Activity: HAL, ADBE, CELG – Nasdaq” with publication date: June 24, 2019.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 5 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Celgene has $103 highest and $95 lowest target. $100.20’s average target is 9.00% above currents $91.93 stock price. Celgene had 17 analyst reports since February 1, 2019 according to SRatingsIntel. The rating was downgraded by Jefferies to “Hold” on Friday, February 1. As per Tuesday, March 12, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating by Jefferies given on Thursday, February 28. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, February 28 by Robert W. Baird. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Mizuho on Monday, June 24. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, February 28 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Monday, June 24 with “Hold”.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.